MedTrace Logo

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

NCT00086216 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-12-21

No results posted yet for this study

Summary

This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.

Conditions

Interventions

DRUG

Atiprimod

Oral, once a day, 14 days on 14 days off

Sponsors & Collaborators

  • Callisto Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gary Jacob, PhD · Callisto Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00086216 on ClinicalTrials.gov